Li Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Li Xu has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Han Wu
Department of Laboratory Medicine, The Second Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524003, P.R. China
3 shared publicationsXiuli Guo
Department of Laboratory Medicine, The Second Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524003, P.R. China
3 shared publicationsXinwang Zhu
Department of Nephrology, The First Hospital of China Medical University, Shenyang, China
2 shared publicationsYing Chen
Department of Nephrology The First Hospital of China Medical University Shenyang China
2 shared publicationsYitian Yang
Respiratory Medicine The Second Affiliated Hospital of Guangdong Medical University Zhanjiang China
2 shared publicationsZhuoting Han
Department of Laboratory Medicine The Second Affiliated Hospital of Guangdong Medical University Zhanjiang China
2 shared publications
Latest Publications
- Open Access
- 13 July 2026
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 58 (3) , 1-13
Tubular PFKFB3 drives diabetic kidney fibrosis via lactate‑dependent H4K12 lactylation and HIPK2 transactivation
Aerobic glycolysis is increasingly recognized as a pathogenic driver in diabetic kidney disease (DKD). However, the epigenetic role of its end product, lactate, remains largely undefined. Spatial transcriptomics analysis revealed active glycolysis in tubular epithelial cells. The participation of histone lactylation in DKD was confirmed through inhibition of histone lactylation by glycolysis inhibitors or lactate in vivo. The potential target genes of H4K12 lactylation (H4K12la) were screened by CUT&Tag analyses. The candidate target genes were validated through ChIP‑qPCR, RT‑qPCR and western blot analyses. The present study found that the expression of 6‑phosphofructo‑2‑kinase/fructose‑2,6‑biphosphatase 3 (PFKFB3), a pivotal glycolytic regulator, was markedly upregulated in tubular epithelial cells derived from patients with DKD and from the corresponding mouse models. Inhibition of the expression of PFKFB3 mitigated the kidney fibrotic process and alleviated renal function in a DKD mouse model. Conversely, upregulation of PFKFB3 expression aggravated renal fibrogenesis and promoted the deterioration of renal pathology. Moreover, it was demonstrated that the reduction in the levels of lactate levels markedly alleviated renal fibrosis in DKD. With regard to its mechanism of action, lactate was generated via PFKFB3‑driven glycolytic reprogramming and selectively enhanced H4K12 lactylation at the homeodomain‑interacting protein kinase 2 (HIPK2) promoter, thereby activating its transcription and driving renal fibrotic progression. These findings indicated that PFKFB3 in renal tubules upregulates HIPK2 expression via facilitating H4K12la‑dependent gene transcription. Therefore, intervention approaches targeting PFKFB3‑triggered HIPK2 activation in tubular cells may offer a novel therapeutic strategy for DKD.
- 13 July 2026
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 58 (3) , 1-13
Open AccessTubular PFKFB3 drives diabetic kidney fibrosis via lactate‑dependent H4K12 lactylation and HIPK2 transactivation
Aerobic glycolysis is increasingly recognized as a pathogenic driver in diabetic kidney disease (DKD). However, the epigenetic role of its end product, lactate, remains largely undefined. Spatial transcriptomics analysis revealed active glycolysis in tubular epithelial cells. The participation of histone lactylation in DKD was confirmed through inhibition of histone lactylation by glycolysis inhibitors or lactate in vivo. The potential target genes of H4K12 lactylation (H4K12la) were screened by CUT&Tag analyses. The candidate target genes were validated through ChIP‑qPCR, RT‑qPCR and western blot analyses. The present study found that the expression of 6‑phosphofructo‑2‑kinase/fructose‑2,6‑biphosphatase 3 (PFKFB3), a pivotal glycolytic regulator, was markedly upregulated in tubular epithelial cells derived from patients with DKD and from the corresponding mouse models. Inhibition of the expression of PFKFB3 mitigated the kidney fibrotic process and alleviated renal function in a DKD mouse model. Conversely, upregulation of PFKFB3 expression aggravated renal fibrogenesis and promoted the deterioration of renal pathology. Moreover, it was demonstrated that the reduction in the levels of lactate levels markedly alleviated renal fibrosis in DKD. With regard to its mechanism of action, lactate was generated via PFKFB3‑driven glycolytic reprogramming and selectively enhanced H4K12 lactylation at the homeodomain‑interacting protein kinase 2 (HIPK2) promoter, thereby activating its transcription and driving renal fibrotic progression. These findings indicated that PFKFB3 in renal tubules upregulates HIPK2 expression via facilitating H4K12la‑dependent gene transcription. Therefore, intervention approaches targeting PFKFB3‑triggered HIPK2 activation in tubular cells may offer a novel therapeutic strategy for DKD.
- Open Access
- 17 April 2026
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 57 (6) , 1-17
IDH2 lactylation regulates mitochondrial dysfunction injury induced by myocardial ischemia‑reperfusion via the AMPK signaling pathway
Ischemic cardiomyopathy ranks as a principal cause of death and incapacity worldwide. Myocardial ischemia‑reperfusion injury (MIRI) caused by percutaneous coronary intervention is a major threat in the treatment of ischemic cardiomyopathy. Although lactylation (Kla) is extensively implicated in numerous pathological processes, its role and specific effects in MIRI remain unclear. Lactylation proteomics was used to identify proteins with different modifications during ischemia‑reperfusion injury. Co‑immunoprecipitation experiments were utilized to detect isocitrate dehydrogenase 2 (IDH2) lactylation levels. Immunofluorescence staining was applied to confirm intracellular lactylation levels. TUNEL, DHE and MitoSOX staining were used to measure oxidative damage in cells and tissues. An oxygen consumption rate experiment and the ATP assay were conducted to determine mitochondrial function. Western blots were utilized to detect changes in proteins related to mitochondrial functional homeostasis and downstream signal alterations. Excessive lactate accumulation was observed in MIRI model mice. This accumulation exacerbated the decline in cardiac function and the damage to cardiomyocytes in mice after MIRI. The lactylation of IDH2 in mitochondria was found to play a regulatory role in mitochondrial dysfunction and MIRI. Regarding the mechanism, it was verified that high IDH2 K275 lactylation caused a reduction in its enzymatic activity and decreased the production of α‑ketoglutarate in the tricarboxylic acid cycle. Consequently, the activation of the AMPK pathway was inhibited, and mitochondrial damage and functional impairment were aggravated. It was also found that SIRT3 regulated and prevented IDH2 lactylation. The results of the present study indicated that IDH2 lactylation, which is elevated due to lactate accumulation and negatively regulated by SIRT3, contributes to the exacerbation of MIRI by regulating the functional homeostasis of mitochondria. This discovery offers a new therapeutic concept and target for MIRI prevention.
- 17 April 2026
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 57 (6) , 1-17
Open AccessIDH2 lactylation regulates mitochondrial dysfunction injury induced by myocardial ischemia‑reperfusion via the AMPK signaling pathway
Ischemic cardiomyopathy ranks as a principal cause of death and incapacity worldwide. Myocardial ischemia‑reperfusion injury (MIRI) caused by percutaneous coronary intervention is a major threat in the treatment of ischemic cardiomyopathy. Although lactylation (Kla) is extensively implicated in numerous pathological processes, its role and specific effects in MIRI remain unclear. Lactylation proteomics was used to identify proteins with different modifications during ischemia‑reperfusion injury. Co‑immunoprecipitation experiments were utilized to detect isocitrate dehydrogenase 2 (IDH2) lactylation levels. Immunofluorescence staining was applied to confirm intracellular lactylation levels. TUNEL, DHE and MitoSOX staining were used to measure oxidative damage in cells and tissues. An oxygen consumption rate experiment and the ATP assay were conducted to determine mitochondrial function. Western blots were utilized to detect changes in proteins related to mitochondrial functional homeostasis and downstream signal alterations. Excessive lactate accumulation was observed in MIRI model mice. This accumulation exacerbated the decline in cardiac function and the damage to cardiomyocytes in mice after MIRI. The lactylation of IDH2 in mitochondria was found to play a regulatory role in mitochondrial dysfunction and MIRI. Regarding the mechanism, it was verified that high IDH2 K275 lactylation caused a reduction in its enzymatic activity and decreased the production of α‑ketoglutarate in the tricarboxylic acid cycle. Consequently, the activation of the AMPK pathway was inhibited, and mitochondrial damage and functional impairment were aggravated. It was also found that SIRT3 regulated and prevented IDH2 lactylation. The results of the present study indicated that IDH2 lactylation, which is elevated due to lactate accumulation and negatively regulated by SIRT3, contributes to the exacerbation of MIRI by regulating the functional homeostasis of mitochondria. This discovery offers a new therapeutic concept and target for MIRI prevention.
- Open Access
- 16 July 2025
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 17 (1) , 1-12
Diagnostic value of the correlation between urinary MDM2 and podocyte mitotic catastrophe in diabetic kidney disease
Podocytic injury and shedding are critical events in the progression and prognosis of diabetic nephropathy (DN). The purpose of our study was to observe heterokaryotic podocytes caused by mitotic catastrophe and the levels of murine double minute gene 2 (MDM2) and synaptopodin (SP) in the urine of patients with diabetic kidney disease (DKD) to explore their value as markers in the early diagnosis of DKD. We examined urine samples from diabetic patients, determined the presence of urinary podocytes and podocyte mitosis catastrophe (PMC), and analyzed their correlations with numerous indicators. Podocytes in urine sediment were observed and counted using immunofluorescence (IF), and the expression of MDM2 and SP in urine supernatant was detected using enzyme-linked immunosorbent assay (ELISA) kits. Podocytes might have been damaged in diabetic patients even during the period of normal albuminuria. Urinary SP level was positively correlated with urinary and heterolytic podocyte counts. MDM2 upregulation in urine was consistent with an increase in albuminuria level and heterolytic podocyte count. The sensitivity of urinary MDM2 to creatine (MDM2/Cr) in the diagnosis of DKD was high, as was the specificity of urinary SP to creatinine (SP/Cr). The diagnostic efficacy of combined urinary MDM2/Cr and SP/Cr was higher than that of either one alone. We observed that PMC and elevated urinary MDM2/Cr levels emerged early in DKD. Additionally, we developed a diagnostic panel combining urinary MDM2/Cr and SP/Cr, which might serve as a predictive tool for early DKD diagnosis and prevention. Urinary podocytes with abnormal nuclear morphology can be detected in the early stages of diabetic kidney disease. Urinary SP/Cr and MDM2/Cr can indicate the development and progression of DM. SP/Cr and MDM2/Cr serve as combined diagnostic biomarkers for early-stage diabetic kidney disease.
- 16 July 2025
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 17 (1) , 1-12
Open AccessDiagnostic value of the correlation between urinary MDM2 and podocyte mitotic catastrophe in diabetic kidney disease
Podocytic injury and shedding are critical events in the progression and prognosis of diabetic nephropathy (DN). The purpose of our study was to observe heterokaryotic podocytes caused by mitotic catastrophe and the levels of murine double minute gene 2 (MDM2) and synaptopodin (SP) in the urine of patients with diabetic kidney disease (DKD) to explore their value as markers in the early diagnosis of DKD. We examined urine samples from diabetic patients, determined the presence of urinary podocytes and podocyte mitosis catastrophe (PMC), and analyzed their correlations with numerous indicators. Podocytes in urine sediment were observed and counted using immunofluorescence (IF), and the expression of MDM2 and SP in urine supernatant was detected using enzyme-linked immunosorbent assay (ELISA) kits. Podocytes might have been damaged in diabetic patients even during the period of normal albuminuria. Urinary SP level was positively correlated with urinary and heterolytic podocyte counts. MDM2 upregulation in urine was consistent with an increase in albuminuria level and heterolytic podocyte count. The sensitivity of urinary MDM2 to creatine (MDM2/Cr) in the diagnosis of DKD was high, as was the specificity of urinary SP to creatinine (SP/Cr). The diagnostic efficacy of combined urinary MDM2/Cr and SP/Cr was higher than that of either one alone. We observed that PMC and elevated urinary MDM2/Cr levels emerged early in DKD. Additionally, we developed a diagnostic panel combining urinary MDM2/Cr and SP/Cr, which might serve as a predictive tool for early DKD diagnosis and prevention. Urinary podocytes with abnormal nuclear morphology can be detected in the early stages of diabetic kidney disease. Urinary SP/Cr and MDM2/Cr can indicate the development and progression of DM. SP/Cr and MDM2/Cr serve as combined diagnostic biomarkers for early-stage diabetic kidney disease.
- Open Access
- 27 May 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (10) , e70627
The Impact of METTL3 on MDM2 Promotes Podocytes Injury During Diabetic Kidney Disease
N6‐Methyladenosine (m6A) methylation plays a role in various pathological processes, including renal fibrosis and aging. Our previous studies have highlighted abnormal expression of the methyltransferase enzyme, methyltransferase like 3 (METTL3), in aging kidney tissues. This study aims to elucidate the regulatory mechanisms of METTL3 in diabetic kidney disease (DKD) by establishing a conditional METTL3 knockout model. We observed elevated m6A levels in the kidneys of type I diabetic mice and in cultured mouse podocytes exposed to advanced glycation end products (AGEs). These increases were attributed to enhanced METTL3 expression. Significantly, podocyte‐specific METTL3 knockdown mitigated injury in streptozotocin (STZ)‐induced diabetic mice, evidenced by reduced urine albuminuria and renal pathology. We discovered that METTL3 induced abnormal m6A modification of murine double minute 2 (MDM2), which triggered its degradation in an IGF2BP2 (insulin‐like growth factor 2 mRNA‐binding protein 2)‐dependent manner. This modification led to increased MDM2 expression, activating the Notch signalling pathway and inducing podocyte cell cycle arrest under diabetic conditions, which further released inflammatory factors and caused podocyte dedifferentiation. Our findings suggest that targeting m6A modification via METTL3 could be an effective strategy for treating DKD.
- 27 May 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (10) , e70627
Open AccessThe Impact of METTL3 on MDM2 Promotes Podocytes Injury During Diabetic Kidney Disease
N6‐Methyladenosine (m6A) methylation plays a role in various pathological processes, including renal fibrosis and aging. Our previous studies have highlighted abnormal expression of the methyltransferase enzyme, methyltransferase like 3 (METTL3), in aging kidney tissues. This study aims to elucidate the regulatory mechanisms of METTL3 in diabetic kidney disease (DKD) by establishing a conditional METTL3 knockout model. We observed elevated m6A levels in the kidneys of type I diabetic mice and in cultured mouse podocytes exposed to advanced glycation end products (AGEs). These increases were attributed to enhanced METTL3 expression. Significantly, podocyte‐specific METTL3 knockdown mitigated injury in streptozotocin (STZ)‐induced diabetic mice, evidenced by reduced urine albuminuria and renal pathology. We discovered that METTL3 induced abnormal m6A modification of murine double minute 2 (MDM2), which triggered its degradation in an IGF2BP2 (insulin‐like growth factor 2 mRNA‐binding protein 2)‐dependent manner. This modification led to increased MDM2 expression, activating the Notch signalling pathway and inducing podocyte cell cycle arrest under diabetic conditions, which further released inflammatory factors and caused podocyte dedifferentiation. Our findings suggest that targeting m6A modification via METTL3 could be an effective strategy for treating DKD.
- 1 December 2024
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 41 (16-18) , 993-1013
M6A RNA Methylation-Mediated TUG1 Stability Maintains Mitochondrial Homeostasis during Kidney Aging by Epigenetically Regulating PGC1-α Expression
Aging is a significant risk factor for the increased incidence of acute kidney injury and chronic kidney disease, posing significant challenges to global public health. The role of N6-methyladenosine (m6A) in the development of chronic kidney disease has been reported, but the regulatory mechanism of m6A in kidney aging remains unclear. In this study, we identified a long non-coding RNA (lncRNA), called TUG1, which exhibited a significantly decreased level of m6A modification in human aged kidney through the m6A-lncRNA epitranscriptome microarray. Bioinformatics analysis and machine learning predicted that TUG1 formed potentially strong interaction with PGC1-α. RIP and ChIP analysis supported that TUG1 promoted proliferator-activated receptor γ coactivator-1α (PGC1-α) expression by directly interact with its TBE region, thereby impacting mitochondrial quality control, cellular senescence and renal fibrosis. Silencing the RNA m6A methylase METTL14 or the reader protein IGF2BP2 resulted in the weakened stability of LncRNA TUG1, contributing to an imbalance in mitochondrial quality control. Our study demonstrated that Our study demonstrated that the m6A modification and stability of TUG1 was mediated by METTL14 in an IGF2BP2-dependent manner, and modulate the mitochondrial homeostasis in kidney aging by direct targeting PGC-1α. These findings provide a new perspective on potential therapeutic targets for kidney aging.
- 1 December 2024
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 41 (16-18) , 993-1013
M6A RNA Methylation-Mediated TUG1 Stability Maintains Mitochondrial Homeostasis during Kidney Aging by Epigenetically Regulating PGC1-α Expression
Aging is a significant risk factor for the increased incidence of acute kidney injury and chronic kidney disease, posing significant challenges to global public health. The role of N6-methyladenosine (m6A) in the development of chronic kidney disease has been reported, but the regulatory mechanism of m6A in kidney aging remains unclear. In this study, we identified a long non-coding RNA (lncRNA), called TUG1, which exhibited a significantly decreased level of m6A modification in human aged kidney through the m6A-lncRNA epitranscriptome microarray. Bioinformatics analysis and machine learning predicted that TUG1 formed potentially strong interaction with PGC1-α. RIP and ChIP analysis supported that TUG1 promoted proliferator-activated receptor γ coactivator-1α (PGC1-α) expression by directly interact with its TBE region, thereby impacting mitochondrial quality control, cellular senescence and renal fibrosis. Silencing the RNA m6A methylase METTL14 or the reader protein IGF2BP2 resulted in the weakened stability of LncRNA TUG1, contributing to an imbalance in mitochondrial quality control. Our study demonstrated that Our study demonstrated that the m6A modification and stability of TUG1 was mediated by METTL14 in an IGF2BP2-dependent manner, and modulate the mitochondrial homeostasis in kidney aging by direct targeting PGC-1α. These findings provide a new perspective on potential therapeutic targets for kidney aging.
- Open Access
- 17 April 2024
- Published by Springer Nature in Research Square
The effect of METTL3 on MDM2 impairs cell cycle homeostasis in podocytes during diabetic kidney disease
N6-Methyladenosine (m6A) methylation is involved in various pathological processes. Our previous study found abnormal expression of the methyltransferases enzyme METTL3 in aging kidney tissues, resulting in renal fibrosis and aging. In this study, we aim to elucidate its regulatory mechanisms in diabetic kidney disease (DKD) by establishing a conditional METTL3 knockout model. We observed elevated m6A levels in the kidney of mice with type I diabetes and in cultured mouse podocytes exposed to advanced glycation end-products (AGEs), which could be attributed to increased METTL3 expression. Podocyte-specific METTL3 knockdown significantly mitigated podocyte injury in streptozotocin (STZ)-induced diabetic mice, leading to reduced urine albuminuria and renal pathology. Mechanistically, METTL3 induced abnormal m6A modification of MDM2, triggering subsequent degradation in an IGF2BP2 dependent manner. Consequently, this abnormal m6A regulation induces increased MDM2 expression, activates the Notch signaling pathway, induced podocyte cell cycle re-entry under diabetic conditions, releases inflammatory factors, and induces dedifferentiation of podocytes. Thus, METTL3-mediated aberrant m6A modification plays a pivotal role in podocytes under diabetic conditions. Targeting m6A via METTL3 is a potentially effective strategy for DKD treatment.
- 17 April 2024
- Published by Springer Nature in Research Square
Open AccessThe effect of METTL3 on MDM2 impairs cell cycle homeostasis in podocytes during diabetic kidney disease
N6-Methyladenosine (m6A) methylation is involved in various pathological processes. Our previous study found abnormal expression of the methyltransferases enzyme METTL3 in aging kidney tissues, resulting in renal fibrosis and aging. In this study, we aim to elucidate its regulatory mechanisms in diabetic kidney disease (DKD) by establishing a conditional METTL3 knockout model. We observed elevated m6A levels in the kidney of mice with type I diabetes and in cultured mouse podocytes exposed to advanced glycation end-products (AGEs), which could be attributed to increased METTL3 expression. Podocyte-specific METTL3 knockdown significantly mitigated podocyte injury in streptozotocin (STZ)-induced diabetic mice, leading to reduced urine albuminuria and renal pathology. Mechanistically, METTL3 induced abnormal m6A modification of MDM2, triggering subsequent degradation in an IGF2BP2 dependent manner. Consequently, this abnormal m6A regulation induces increased MDM2 expression, activates the Notch signaling pathway, induced podocyte cell cycle re-entry under diabetic conditions, releases inflammatory factors, and induces dedifferentiation of podocytes. Thus, METTL3-mediated aberrant m6A modification plays a pivotal role in podocytes under diabetic conditions. Targeting m6A via METTL3 is a potentially effective strategy for DKD treatment.
- 13 February 2024
- Published by Springer Nature in Biogerontology
- Vol. 25 (3) , 399-414
Renal aging and mitochondrial quality control
Mitochondria are dynamic organelles that participate in different cellular process that control metabolism, cell division, and survival, and the kidney is one of the most metabolically active organs that contains abundant mitochondria. Perturbations in mitochondrial homeostasis in the kidney can accelerate kidney aging, and maintaining mitochondrial homeostasis can effectively delay aging in the kidney. Kidney aging is a degenerative process linked to detrimental processes. The significance of aberrant mitochondrial homeostasis in renal aging has received increasing attention. However, the contribution of mitochondrial quality control (MQC) to renal aging has not been reviewed in detail. Here, we generalize the current factors contributing to renal aging, review the alterations in MQC during renal injury and aging, and analyze the relationship between mitochondria and intrinsic renal cells. We also introduce MQC in the context of renal aging, and discuss the study of mitochondria in the intrinsic cells of the kidney, which is the innovation of our paper. In addition, during kidney injury and repair, the specific functions and regulatory mechanisms of MQC systems in resident and circulating cell types remain unclear. Currently, most of the studies we reviewed are based on animal and cellular models, the relationship between renal tissue aging and mitochondria has not been adequately investigated in clinical studies, and there is still a long way to go.
- 13 February 2024
- Published by Springer Nature in Biogerontology
- Vol. 25 (3) , 399-414
Renal aging and mitochondrial quality control
Mitochondria are dynamic organelles that participate in different cellular process that control metabolism, cell division, and survival, and the kidney is one of the most metabolically active organs that contains abundant mitochondria. Perturbations in mitochondrial homeostasis in the kidney can accelerate kidney aging, and maintaining mitochondrial homeostasis can effectively delay aging in the kidney. Kidney aging is a degenerative process linked to detrimental processes. The significance of aberrant mitochondrial homeostasis in renal aging has received increasing attention. However, the contribution of mitochondrial quality control (MQC) to renal aging has not been reviewed in detail. Here, we generalize the current factors contributing to renal aging, review the alterations in MQC during renal injury and aging, and analyze the relationship between mitochondria and intrinsic renal cells. We also introduce MQC in the context of renal aging, and discuss the study of mitochondria in the intrinsic cells of the kidney, which is the innovation of our paper. In addition, during kidney injury and repair, the specific functions and regulatory mechanisms of MQC systems in resident and circulating cell types remain unclear. Currently, most of the studies we reviewed are based on animal and cellular models, the relationship between renal tissue aging and mitochondria has not been adequately investigated in clinical studies, and there is still a long way to go.
- Open Access
- 17 January 2024
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 53 (3) , 1-12
Senolytic combination of dasatinib and quercetin protects against diabetic kidney disease by activating autophagy to alleviate podocyte dedifferentiation via the Notch pathway
The senolytics dasatinib and quercetin (DQ) alleviate age‑related disorders. However, limited information is available regarding the effects of DQ on diabetic kidney disease (DKD). The present study aimed to explore the effects of DQ on DKD and its potential molecular mechanism(s). Dasatinib (5 mg/kg) and quercetin (50 mg/kg) were administered to diabetic db/db mice by gavage for 20 weeks. Body weight, urine albumin‑creatinine ratio (ACR), serum creatinine (Scr), and blood urea nitrogen (BUN) were recorded at the indicated time periods. Periodic acid‑Schiff and Masson's staining were performed to assess the histopathological changes of kidney tissues. Immunohistochemical analysis, immunofluorescence and western blotting were performed to evaluate the expression levels of extracellular matrix (ECM) proteins, autophagic and podocyte differentiation‑related proteins. In addition, mouse podocytes were administered with high‑glucose, DQ and 3‑methyladenine (3‑MA), and the expression levels of autophagic and podocyte differentiation‑related proteins were measured. Moreover, following overexpression of the Notch intracellular domain (NICD), the expression levels of NICD, autophagic and podocyte differentiation‑related proteins were further assessed. DQ significantly reduced the body weight, blood glucose, ACR, Scr and BUN levels and improved the histopathological changes induced in diabetic db/db mice. In addition, DQ caused a significant downregulation of the expression levels of the ECM proteins, improved autophagy and induced an upregulation of the expression levels of podocyte differentiation‑related proteins. Administration of 3‑MA to mice significantly reduced podocyte differentiation, and overexpression of NICD could reverse the effects of DQ on autophagy and podocyte differentiation in vitro. The present study suggests that DQ protects against DKD by activation of autophagy to alleviate podocyte dedifferentiation via the Notch pathway.
- 17 January 2024
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 53 (3) , 1-12
Open AccessSenolytic combination of dasatinib and quercetin protects against diabetic kidney disease by activating autophagy to alleviate podocyte dedifferentiation via the Notch pathway
The senolytics dasatinib and quercetin (DQ) alleviate age‑related disorders. However, limited information is available regarding the effects of DQ on diabetic kidney disease (DKD). The present study aimed to explore the effects of DQ on DKD and its potential molecular mechanism(s). Dasatinib (5 mg/kg) and quercetin (50 mg/kg) were administered to diabetic db/db mice by gavage for 20 weeks. Body weight, urine albumin‑creatinine ratio (ACR), serum creatinine (Scr), and blood urea nitrogen (BUN) were recorded at the indicated time periods. Periodic acid‑Schiff and Masson's staining were performed to assess the histopathological changes of kidney tissues. Immunohistochemical analysis, immunofluorescence and western blotting were performed to evaluate the expression levels of extracellular matrix (ECM) proteins, autophagic and podocyte differentiation‑related proteins. In addition, mouse podocytes were administered with high‑glucose, DQ and 3‑methyladenine (3‑MA), and the expression levels of autophagic and podocyte differentiation‑related proteins were measured. Moreover, following overexpression of the Notch intracellular domain (NICD), the expression levels of NICD, autophagic and podocyte differentiation‑related proteins were further assessed. DQ significantly reduced the body weight, blood glucose, ACR, Scr and BUN levels and improved the histopathological changes induced in diabetic db/db mice. In addition, DQ caused a significant downregulation of the expression levels of the ECM proteins, improved autophagy and induced an upregulation of the expression levels of podocyte differentiation‑related proteins. Administration of 3‑MA to mice significantly reduced podocyte differentiation, and overexpression of NICD could reverse the effects of DQ on autophagy and podocyte differentiation in vitro. The present study suggests that DQ protects against DKD by activation of autophagy to alleviate podocyte dedifferentiation via the Notch pathway.